ATOPIC DERMATITIS (AD)

This study looks at how safe and effective Stapokibart injection is for adults with moderate-to-severe atopic dermatitis (eczema). About 1,000 people will take part, and their doctors have already decided to use this drug. The main goal is to track any side effects related to the…

This study tests an approved eczema drug, ivarmacitinib, in 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis (a type of eczema). Researchers want to see how well it reduces itching and clears skin rashes over 16 weeks, and to gather safety information. Partici…

This study tests an experimental drug called SIM0278 for adults with moderate to severe atopic dermatitis (eczema). About 184 participants will receive either a low, medium, or high dose of the drug or a placebo. The main goal is to see how much eczema symptoms improve after 16 w…

This study compares a new medicine called GS101 to the existing drug Dupixent for people with moderate-to-severe atopic dermatitis (eczema). About 572 adults will receive either GS101 or Dupixent to see which works better at clearing skin and reducing itch. The main goal is to me…

This study looks at whether a pill called ivarmacitinib can help people with moderate-to-severe eczema (atopic dermatitis) who didn't get better after using other injectable medications. About 300 adults will take the pill for 16 weeks, and doctors will check if their skin rash a…

This early-phase study tests an experimental drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The main goal is to check safety and how the body processes the drug. Researchers will also look at early signs of effecti…

This study tests a medicated foam (1% OPA-15406) for adults with atopic dermatitis (eczema). About 156 people with mild to moderate eczema will use the foam or a placebo for 4 weeks. The goal is to see if the foam can clear or nearly clear the skin better than the placebo.

This study tests whether a cream called crisaborole can help people with mild to moderate eczema. About 270 people aged 12 to 50 will use either the cream or a placebo twice a day for four weeks. The goal is to see if the cream clears or nearly clears the skin better than the pla…

This study tests a medicated foam (OPA-15406) for children with atopic dermatitis, a common skin condition causing red, itchy skin. About 198 children, including infants under 2, will use the foam daily for 4 weeks. The goal is to see if the foam can clear or nearly clear the ras…

This study tests whether a newer cream (crisaborole) works as well as a standard cream (tacrolimus) for children aged 2–18 with mild to moderate eczema. About 66 kids will use one of the two creams twice daily for 28 days. The main goal is to see how many achieve clear or almost …

This study looks at whether teens with eczema prefer to moisturize while still in the shower or after towel drying. Researchers will measure skin hydration, itchiness, and eczema severity to see which method works better. Thirty participants aged 12-18 will try both techniques fo…

This early-stage study will test whether a special headband can detect changes in brain activity related to pain, itching, and discomfort in 20 adults with mild to moderate eczema. Participants will have a single visit where a marketed skin product or water is applied, and their …

This study will follow 50 Costa Rican adults with moderate-to-severe atopic dermatitis (eczema) who are already receiving advanced treatments like dupilumab or JAK inhibitors as part of their routine care. Researchers will collect data from regular doctor visits to see how sympto…